Advertisement

Non-Viral Hepatitis Outbreak Linked to Weight-Loss Supplement — Physician’s First Watch

Medical News |
October 10, 2013

Non-Viral Hepatitis Outbreak Linked to Weight-Loss Supplement

By Kelly Young

At least 24 people have developed acute non-viral hepatitis after using the dietary supplement OxyElite Pro, marketed for use in weight loss and muscle building. Additionally, two patients have received liver transplants, and one patient died, but it is not clear whether they took OxyElite Pro or a different dietary supplement.

The cases (median age, 33) all lived in Hawaii, but the CDC is investigating whether there are cases of liver injury elsewhere, since the supplement is sold nationwide. The FDA advises consumers to stop using OxyElite Pro during the investigation.

The CDC recommends that clinicians examining patients with acute hepatitis should ask about their dietary supplement use. Patients meeting the case definition (i.e., used a dietary supplement within 60 days of symptom onset and have alanine transaminase more than 4 times the upper limit of normal, total bilirubin more than twice the upper limit of normal, and negative workup for other potential causes) should be reported to state or local health departments and the FDA's MedWatch program.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement